ArticleScientific reports2026
A 5mC-related gene signature predicts prognosis and therapy response in hepatocellular carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Increasing evidence has highlighted the biological significance of 5-methylcytosine (5mC) DNA modification in regulating tumorigenesis and cancer progression. However, the potential roles of the 5mC modification in HCC are still unknown. A consensus clustering algorithm was performed to determine 5mC modification patterns and establish a 5mC-related gene signature in HCC. Weighted gene co‑expression network analysis (WGCNA) integrated with machine learning approaches (LASSO, RF, and SVM‑RFE) was applied to identify candidate biomarkers, and a 5mC risk score model was subsequently constructed. The concordance index (C‑index), decision curve analysis (DCA), and ROC curve were employed to evaluate the performance of the nomogram. Two distinct 5mC modification patterns were identified, with cluster B exhibiting worse prognosis and enrichment of cell cycle and metabolic pathways. Using integrated WGCNA and machine learning, we constructed a three-gene (DNMT1, SPATS2, MCM6) risk score model that effectively stratified patients into high- and low-risk groups with significantly different overall survival. The risk score demonstrated robust prognostic performance across independent cohorts and was an independent prognostic factor. High risk scores correlated with advanced stage, higher tumor mutational burden, distinct immune microenvironment features, and increased sensitivity to multiple chemotherapeutic and targeted agents. A nomogram incorporating the risk score and clinicopathological features showed acceptable predictive accuracy and clinical net benefit. Experimental validation confirmed upregulation of DNMT1 and SPATS2 in HCC tissues, and their knockdown suppressed HCC cell proliferation, migration, and invasion. The 5mC risk model demonstrates clinical applicability and net benefit in terms of prognostic stratification, immunophenotype characterization, and prediction of drug therapy response in HCC patients, providing a useful tool for precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.